IRE-1α inhibitors
US9040714B2 · kind B2 · utility
5Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 5, 2011 |
| Grant date | May 26, 2015 |
| Priority date | — |
| Expiry date | Apr 5, 2031 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.